Targeting the Lysosomal Degradation of Rab22a‐NeoF1 Fusion Protein for Osteosarcoma Lung Metastasis
Advanced Science · 2023-02 · 10 (5)
DOI: 10.1002/advs.202205483 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 18.12.2022. Verfasst von Cuiling Zeng und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou…. Hauptthemen laut MEDLINE: Lung Neoplasms, Osteosarcoma, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Nature Science Foundation in China, Science and Technology Program of Guangzhou.
Abstract (Originalsprache)
Rab22a‐NeoF fusion protein has recently been reported as a promising target for osteosarcoma lung metastasis. However, how this fusion protein is regulated in cells remains unknown. Here, using multiple screenings, it is reported that Rab22a‐NeoF1 fusion protein is degraded by an E3 ligase STUB1 via the autophagy receptor NDP52‐mediated lysosome pathway, which is facilitated by PINK1 kinase. Mechanistically, STUB1 catalyzes the K63‐linked ubiquitin chains on lysine112 of Rab22a‐NeoF1, which is responsible for the binding of Rab22a‐NeoF1 to NDP52, resulting in lysosomal degradation of Rab22a‐NeoF1. PINK1 is able to phosphorylate Rab22a‐NeoF1 at serine120, which promotes ubiquitination and degradation of Rab22a‐NeoF1. Consistently, by upregulating PINK1, Sorafenib and Regorafenib can inhibit osteosarcoma lung metastasis induced by Rab22a‐NeoF1. These findings reveal that the lysosomal degradation of Rab22a‐NeoF1 fusion protein is targetable for osteosarcoma lung metastasis, proposing that Sorafenib and Regorafenib may benefit cancer patients who are positive for the RAB22A ‐NeoF1 fusion gene.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
- Center of Digestive Diseases, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, China.
- Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
- Department of Oncology, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, 519000, China.
ORCID-Profile: Dan Liao
Förderung
- National Key Research and Development Program of China
- National Nature Science Foundation in China
- Science and Technology Program of Guangzhou
- Natural Science Foundation of Guangdong Province for Distinguished Young Scholars
- Key program of sun yat-sen university for young teacher
- Research Start-up Fund of the Seventh Affiliated Hospital, Sun Yat-sen University
- Shenzhen Science and Technology Program
Zitieren
APA
Zeng, C., Zhong, L., Liu, W., Zhang, Y., Yu, X., Wang, X., Zhang, R., Kang, T., & Liao, D. (2023). Targeting the Lysosomal Degradation of Rab22a‐NeoF1 Fusion Protein for Osteosarcoma Lung Metastasis. Advanced Science, 10(5). https://doi.org/10.1002/advs.202205483
Vancouver
Zeng C, Zhong L, Liu W, Zhang Y, Yu X, Wang X, et al. Targeting the Lysosomal Degradation of Rab22a‐NeoF1 Fusion Protein for Osteosarcoma Lung Metastasis. Advanced Science. 2023;10(5). doi:10.1002/advs.202205483
BibTeX
@article{Zeng2023,
author = {Zeng, Cuiling and Zhong, Li and Liu, Wenqiang and Zhang, Yu and Yu, Xinhao and Wang, Xin and Zhang, Ruhua and Kang, Tiebang and Liao, Dan},
title = {Targeting the Lysosomal Degradation of Rab22a‐NeoF1 Fusion Protein for Osteosarcoma Lung Metastasis},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {5},
doi = {10.1002/advs.202205483}
}
EUVIMED